Coya Therapeutics (NASDAQ: COYA) director granted new 10,000 options

Rhea-AI Filing Summary

Coya Therapeutics, Inc. director Lee Ann reported receiving a stock option grant. On January 2, 2026, she was granted a stock option to buy 10,000 shares of common stock with an exercise price of $5.65 per share.

The option was granted for no cash cost and is held directly. Subject to continuous service, 100% of the option vests on the first anniversary of the grant date. The option becomes exercisable on January 2, 2027 and is scheduled to expire on January 2, 2036. Following this grant, Lee Ann beneficially owns 10,000 derivative securities in the form of this option.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Ann

(Last) (First) (Middle)

5850 SAN FELIPE ST., SUITE 500

(Street)

HOUSTON TX 77057

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coya Therapeutics, Inc. [ COYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.65	01/02/2026		A		10,000		01/02/2027(1)	01/02/2036	Common Stock, par value $0.0001 per share	10,000	$0.00	10,000	D

Explanation of Responses:

1. Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.

	/s/ David Snyder, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Coya Therapeutics (COYA) report?

Coya Therapeutics reported that director Lee Ann received a grant of a stock option on January 2, 2026, covering 10,000 shares of common stock.

How many Coya Therapeutics (COYA) shares are covered by the new option grant?

The stock option granted to director Lee Ann covers 10,000 shares of Coya Therapeutics common stock.

What is the exercise price of the Coya Therapeutics (COYA) stock option granted to the director?

The stock option granted to director Lee Ann has an exercise price of $5.65 per share for Coya Therapeutics common stock.

When do the new Coya Therapeutics (COYA) stock options vest and expire?

Subject to continuous service, 100% of the option vests on the first anniversary of the January 2, 2026 grant date and is scheduled to expire on January 2, 2036.

How many derivative securities does the Coya Therapeutics (COYA) director own after this transaction?

After this transaction, director Lee Ann beneficially owns 10,000 derivative securities, represented by this stock option, held directly.

What role does the reporting person have at Coya Therapeutics (COYA)?

The reporting person, Lee Ann, is identified as a director of Coya Therapeutics, Inc. and is not listed as an officer or 10% owner.